The Zika virus builds tiny tunnels, called tunneling nanotubes, to stealthily transport material needed to infect nearby ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Supercomputer simulations have revealed how changes in the shape of the HIV-1 capsid protein may help the virus squeeze its inner core into the host cell's nuclear membrane. The findings ...

which is a protein the CNS releases in response to injury. Latus’ other lead gene therapy uses its AAV-Ep+ capsid to target ependymal cells as well as neurons. Ependymal cells secrete proteins ...

LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV replication. Unlike traditional antiretrovirals that target enzymes such as ...